The historical rank and industry rank for Vistagen Therapeutics's FCF Margin % or its related term are showing as below:
VTGN'
s FCF Margin % Range Over the Past 10 Years
Min: -8701.23 Med: -2431.77 Max: 21994.71
Current: -5243.07
During the past 13 years, the highest FCF Margin % of Vistagen Therapeutics was 21994.71%. The lowest was -8701.23%. And the median was -2431.77%.
VTGN's FCF Margin % is ranked worse than 91.03% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs VTGN: -5243.07
Vistagen Therapeutics FCF Margin % Related Terms
Vistagen Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Vistagen Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vistagen Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (VTGN) has a FCF Margin % of -3,483.87% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vistagen Therapeutics and its competitors. According to the industry distribution chart, Vistagen Therapeutics ranks #873 out of 959 companies in the Biotechnology industry, placing it in the top 91%.
Is Vistagen Therapeutics' FCF Margin % too high?
Vistagen Therapeutics' current FCF Margin % is -3,483.87%. Based on the distribution chart, Vistagen Therapeutics ranks #873 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' FCF Margin % compare to PLUR and PTN?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #873 out of 959 companies for FCF Margin %. This places Vistagen Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current FCF Margin % is -3,483.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.67 — trading 69.7% below its estimated fair value. The current FCF Margin % is -3,483.87%. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current FCF Margin % is -3,483.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of $0.67 is trading 69.7% below its estimated GF Value™ of $2.20.
GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.
Key valuation signals for VTGN:
FCF Margin %: -3,483.87%
GF Value™: $2.20 vs. price of $0.67 (69.7% below fair value)
No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score
Get the complete analysis for VTGN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTGN has been successfully added to your 
